# US 6,727,230 B1 · Immune stimulation by phosphorothioate oligonucleotide analogs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,230 B1
- Document ID: US6727230B1
- Status: Granted
- Kind: B1
- Application number: 09/009,634
- Filed: 1998-01-20
- Granted: 2004-04-27
- Earliest claimed: 1994-03-25
- Assignees: Coley Pharmaceutical Group, Inc.
- Inventors: Stephen L. Hutcherson; Josephine M. Glover
- Web page: https://patentgrep.com/patent/US6727230B1

## CPC

- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/7125: Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- C12N 15/1131: {against viruses}
- C12N 15/1133: {against herpetoviridae, e.g. HSV}
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- C12N 15/117: Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/18: acting by a non-sequence specific mechanism
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Methods of stimulating a local immune response in selected cells or tissues employing immunopotentiating oligonucleotide analogs having at least one phosphorothioate internucleotide bond are provided. Methods of enhancing the efficacy of a therapeutic treatment by stimulating a local immune response in selected cells or tissues employing oligonucleotide analogs having at least one phosphorothioate bond are also provided. The oligonucleotide analogs may have antisense efficacy in addition to immunopotentiating activity. Methods of modulating cytokine release in skin cells and immunopotentiators which include oligonucleotide analogs having at least one phosphorothioate bond capable of eliciting a local inflammatory response are also provided.

## Claims

### Claim 1

A method for treating prophylactically a human to stimulate a cell-mediated immune response comprising:
administering to the human as an immunopotentiator an amount of a phosphorothioate oligonucleotide analog effective to stimulate a cell-mediated immune response.

### Claim 2 (depends on 1)

The method of claim 1, wherein the phosphorothioate oligonucleotide analog is not antisense.

### Claim 3

A method for treating a human who has cancer comprising:
administering to the human as an immunopotentiator an amount of a phosphorothioate oligonucleotide analog effective to stimulate a cell-mediated immune response.

### Claim 4 (depends on 3)

The method of claim 3, wherein the phosphorothioate oligonucleotide analog is not antisense.

### Claim 5

A method for treating a human who has an infection comprising:
administering to the human as an immunopotentiator an amount of a phosphorothioate oligonucleotide analog effective to stimulate a cell-mediated immune response.

### Claim 6 (depends on 5)

The method of claim 5, wherein the phosphorothioate oligonucleotide analog is not antisense.

### Claim 7

A method for treating a human having surgery comprising:
administering to the human as an immunopotentiator in conjunction with the surgery an amount of a phosphorothioate oligonucleotide analog effective to stimulate a cell-mediated immune response.

### Claim 8 (depends on 7)

The method of claim 7, wherein the phosphorothioate oligonucleotide analog is not antisense.

### Claim 9

A method for treating therapeutically a human, comprising:
administering to a human subject in need of such treatment as an immunopotentiator an amount of a phosphorothioate oligonucleotide analog effective to stimulate a cell-mediated immune response, wherein the phosphorothioate oligonucleotide analog is not antisense.

### Claim 10

A method of enhancing the efficacy of a therapeutic or prophylactic treatment for a human subject by stimulating a cell-mediated immune response, comprising:
administering to the human subject as an immunopotentiator in conjunction with the treatment an amount of a phosphorothioate oligonucleotide analog effective to stimulate a cell-mediated immune response.

### Claim 11 (depends on 10)

The method of claim 10, wherein the phosphorothioate oligonucleotide analog is not antisense.

### Claim 12 (depends on 10)

The method of claim 10, wherein the treatment is an anti-infective agent.

### Claim 13 (depends on 10)

The method of claim 10, wherein the treatment is an anti-cancer agent.

### Claim 14 (depends on 10)

The method of claim 10, wherein the treatment is surgery.
